Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization

Santos, Nayara F B Dos; Silva, Lukas Raposo da; Costa, Fagner James Martins Dantas; Mattos, Daniely Maranhão de; Carvalho, Enéas; Ferreira, Luís Carlos de Souza; Ferreira, Rita de Cássia Café

doi:10.1016/j.vaccine.2020.05.076

Cited by 7 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody response after immunization was examined in ELISA assay in which plates were coated with BibA protein. This indirect use indicates the usability of BibA protein as detection antigen in ELISA for GBS carriage and/or infection diagnosis [60]. A similar conclusion can be drawn from the research whose aim was to examine the association between antibodies against Streptococcus agalactiae surface proteins and recto-vaginal colonization during pregnancy, in which titers of IgG antibodies were measured in Luminex multiplex immunoassay [61].…”

Section: Biba Proteinsupporting

confidence: 58%

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Dobrut

Brzychczy-Włoch

2021

Pathogens

View full text Add to dashboard Cite

Streptococcus agalactiae (Group B Streptococcus, GBS) is an opportunistic pathogen, which asymptomatically colonizes the gastrointestinal and genitourinary tract of up to one third of healthy adults. Nevertheless, GBS carriage in pregnant women may lead to several health issues in newborns causing life threatening infection, such as sepsis, pneumonia or meningitis. Recommended GBS screening in pregnant women significantly reduced morbidity and mortality in infants. Nevertheless, intrapartum antibiotic prophylaxis, recommended following the detection of carriage or in case of lack of a carriage test result for pregnant women who demonstrate certain risk factors, led to the expansion of the adverse phenomenon of bacterial resistance to antibiotics. In our paper, we reviewed some immunogenic GBS proteins, i.e., Alp family proteins, β protein, Lmb, Sip, BibA, FsbA, ScpB, enolase, elongation factor Tu, IMPDH, and GroEL, which possess features characteristic of good candidates for immunodiagnostic assays for GBS carriage detection, such as immunoreactivity and specificity. We assume that they can be used as an alternative diagnostic method to the presently recommended bacteriological cultivation and MALDI.

show abstract

Section: Biba Proteinsupporting

confidence: 58%

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Dobrut

Brzychczy-Włoch

2021

Pathogens

View full text Add to dashboard Cite

show abstract

“…A similar mouse model determined that maternal vaccination with a C5a peptidase-containing vaccine protected neonates against lethal challenge and, furthermore, prevented subsequent vaginal colonization of the dam (Santillan et al, 2008;Santillan et al, 2011). BibA also holds promise as a vaccine, as mucosal vaccination with recombinant BibA resulted in protection of mice against both systemic and vaginal challenge (dos Santos et al, 2020).…”

Section: Novel Prophylactics To Prevent Vaginal Colonizationmentioning

confidence: 99%

Bacterial and Host Determinants of Group B Streptococcal Vaginal Colonization and Ascending Infection in Pregnancy

Brokaw

Furuta

Dacanay

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Group B streptococcus (GBS) is a gram-positive bacteria that asymptomatically colonizes the vaginal tract. However, during pregnancy maternal GBS colonization greatly predisposes the mother and baby to a wide range of adverse outcomes, including preterm birth (PTB), stillbirth, and neonatal infection. Although many mechanisms involved in GBS pathogenesis are partially elucidated, there is currently no approved GBS vaccine. The development of a safe and effective vaccine that can be administered during or prior to pregnancy remains a principal objective in the field, because current antibiotic-based therapeutic strategies do not eliminate all cases of invasive GBS infections. Herein, we review our understanding of GBS disease pathogenesis at the maternal-fetal interface with a focus on the bacterial virulence factors and host defenses that modulate the outcome of infection. We follow GBS along its path from an asymptomatic colonizer of the vagina to an invasive pathogen at the maternal-fetal interface, noting factors critical for vaginal colonization, ascending infection, and vertical transmission to the fetus. Finally, at each stage of infection we emphasize important host-pathogen interactions, which, if targeted therapeutically, may help to reduce the global burden of GBS.

show abstract

“…The six conserved GBS proteins were: (1) sortase A (SrtA), which is necessary for anchoring cell wall proteins (including many virulence factors) [ 22 ]; (2) cell-surface-associated protein A (CspA), which cleaves CXC chemokines [ 23 ]; (3) C5a peptidase (ScpB), which specifically cleaves complement-activated C5a, abolishing neutrophil recruitment to the infection site [ 24 ]; (4) a secreted fibrinogen-binding protein (FbsB), which enhances GBS internalization into epithelial cells [ 25 ]; (5) fibrinogen-binding protein with serine-rich repeat 2 (Srr2), which increases the permeability of the blood–brain barrier [ 26 ], and (6) an immunogenic bacterial adhesin (BibA), which specifically binds to C4-binding protein to resist opsonophagocytic killing by neutrophils [ 21 , 27 ]. These proteins have been reported to elicit protective antibodies [ 28 , 29 , 30 , 31 ] or serotype-independent protection [ 32 , 33 ]. Vaginal mucosal immunity is necessary for efficient local GBS clearance [ 34 ].…”

Section: Introductionmentioning

confidence: 99%

Immunization with Multiple Virulence Factors Provides Maternal and Neonatal Protection against Group B Streptococcus Serotypes

Wang,

Li,

et al. 2023

Vaccines

View full text Add to dashboard Cite

Group B streptococcus (GBS) commonly colonizes the vaginal tract and is a leading cause of life-threatening neonatal infections and adverse pregnancy outcomes. No effective vaccine is clinically available. Conserved bacterial virulence factors, including those of GBS, have been employed as vaccine components. We investigated serotype-independent protection against GBS by intranasal immunization with six conserved GBS virulence factors (GBSV6). GBSV6 induced systemic and vaginal antibodies and T cell responses in mice. The immunity reduced mouse mortality and vaginal colonization by various GBS serotypes and protected newborn mice of immunized dams against GBS challenge. Intranasal GBSV6 immunization also provided long-lasting protective immunity and had advantages over intramuscular GBSV6 immunization regarding restricting vaginal GBS colonization. Our findings indicate that intranasal immunization targeting multiple conserved GBS virulence factors induces serotype-independent immunity, which protects against GBS infection systemically and vaginally in dams and prevents newborn death. The study presents valuable strategies for GBS vaccine development.

show abstract

Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization

Cited by 7 publications

References 49 publications

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Bacterial and Host Determinants of Group B Streptococcal Vaginal Colonization and Ascending Infection in Pregnancy

Immunization with Multiple Virulence Factors Provides Maternal and Neonatal Protection against Group B Streptococcus Serotypes

Contact Info

Product

Resources

About